Sameer Rastogi/X
Jun 6, 2025, 05:11
Sameer Rastogi: Thank you, OncoDaily, for recognizing our study, the SORASTOP trial
Sameer Rastogi, Additional Professor at All India Institute of Medical Sciences, shared a post on LinkedIn:
“Thank you, OncoDaily, for recognizing our study, the SORASTOP trial.
We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with desmoid tumors who are responding to treatment.
Median duration of sorafenib therapy was 24 months (range: 14.5–33.5), and at a median follow-up of 15 months (range: 9–18), 20 patients were evaluable.
Among the 20 evaluable patients, the 1-year change in tumour size ranged from a 21% decrease to a 32% increase. Three patients restarted sorafenib because of pain with stable disease (n = 2) and radiological progression (n = 1).
6-month and 1-year PFR were 96.7% and 95%, respectively.
Statistically significant quality of life (QoL) improvement was demonstrated in insomnia (p = 0.01), diarrhea (p = 0.02), physical (p < 0.001), and social (p = 0.04) functioning at 12 months, while neurocognitive functions remained stable.
Mature data will be presented this year.
First study to address the duration of sorafenib, Longer follow up needed.
Thanks to Simran Kaur, Rashi Kapoor, Lakshay Nagpal, The Desmoid Tumor Research Foundation (DTRF), AIIMS (All India Institute of Medical Sciences, New Delhi) for help.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 14:53
Jun 7, 2025, 14:10